Drug Profile
Tipiracil/trifluridine - Taiho Pharmaceutical
Alternative Names: FTD/TPI; Lonsurf; Orcantas; S 95005; S 95005/TAS-102; T15, T20; T15/T20; TAS-102; TAS-102/S-95005; Tipiracil-hydrochloride/trifluridine; Trifluridine/tipiracil; Trifluridine/tipiracil hydrochlorideLatest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Developer Amgen; Baylor Research Institute; Emory University; Ipsen; Servier; Taiho Oncology; Taiho Pharmaceutical; TTY Biopharm; University of Florida; University of Wisconsin-Madison
- Class Antineoplastics; Nucleosides; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action DNA synthesis inhibitors; Thymidine phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Colorectal cancer; Gastric cancer
- Phase II Bladder cancer; Cholangiocarcinoma; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Squamous cell cancer
- Phase I/II Gastrointestinal cancer
- No development reported Solid tumours
Most Recent Events
- 18 Jan 2024 Pharmacodynamics and efficacy data from phase I trial in Colorectal cancer presented at Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 18 Jan 2024 Updated adverse events data from a phase III clinical trial in Colorectal cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 05 Jan 2024 Indiana University and Taiho technology terminates a phase I trial in Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) due to neulasta difficulties and other complications (NCT04046887)